Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients

Journal of Trauma - Injury, Infection and Critical Care

Volumn 59, Issue 6, 2005, Pages 1336-1344

  Haas, Curtis E ^a,c,d   Nelsen, Jamie L ^a,c   Raghavendran, Krishnan ^b,c   Mihalko, William ^b,c   Beres, Joseph ^a,c   Ma, Qing ^a,c   Forrest, Alan ^a,b,c   Grubler, K Dean ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

^d NONE

Author keywords

Critical illness; Exoxaparin; Low molecular weight Heparin; Multiple trauma; Pharmacokinetics; Venous thrombosis

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; ENOXAPARIN; FIBRINOLYTIC AGENT; PHARMACOKINETICS; THROMBIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; BLOOD; BLOOD SAMPLING; BODY WEIGHT; CHROMOGENIC ASSAY; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLICATION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; EDEMA; ETIOLOGY; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; METABOLISM; MIDDLE AGED; MULTIPLE TRAUMA; PARAMETER; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANK SUM TEST; RELIABILITY; UNITED STATES; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTAGONISTS AND INHIBITORS; ANTITHROMBIN III; BLOOD; COHORT STUDIES; COMPLICATIONS; CRITICAL ILLNESS; EDEMA; ENOXAPARIN; ETIOLOGY; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; METABOLISM; MIDDLE AGED; MULTIPLE TRAUMA; PHARMACOKINETICS;

EID: 33646174432     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ta.0000197354.69796.bd     Document Type: Article

References (33)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S-400S.
2. Rogers F. Venous thromboembolism in trauma patients: a review. Surgery. 2001;130:1-12.
3. Kelsey L, Fry D, Vanderkolk W. Thrombosis risk in the trauma patient. Prevention and treatment. Hematol Oncol Clin North Am. 2000;14:417-430.
4. Geerts W, Code K, Jay R, Chen E, Szalai J. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331:1601-1606.
5. Schultz DJ, Brasel KJ, Washington L, et al. Incidence of asymptomatic pulmonary embolism in moderately to severely injured trauma patients. J Trauma. 2004;56:727-733.
6. Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma. 2002;53:142-164.
7. Geerts W, Jay R, Code K, et al. A comparison of low dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707.
8. Knudson M, Morabito D, Paiement G, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. J Trauma. 1996;41:446-459.
9. Owings J, Bagley M, Gosselin R, Romac D, Disbrow E. Effect of critical injury on plasma antithrombin activity: Low antithrombin levels are associated with thromboembolic complications. J Trauma. 1996;41:396-406.
10. Penner J. Antithrombin deficiency in special clinical syndromes - Part II: Trauma/burns. Semin Hematol. 1995;32(Suppl 2):42-47.
11. Dorffler-Melly J, de Jonge E, de Pont A, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002;359:849-850.
12. Mayr A, Dunser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002;105:201-204.
13. Priglinger U, Karth D, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003;31:1405-1409.
14. Yogaratnam D, Smith BS, Angood PB, Gandhi PJ. Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism. Pharmacotherapy. 2004;24:1793-1799.
15. Collignon F, Frydman A, Caplain H. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin, and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73:630-640.
16. Azizi M, Veyssier-Belot C, Alhenc-Gelas M, et al. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Pharmacol. 1995;40:577.
17. Bendetowicz A, Beguin S, Caplain H. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin -a three way cross over study in human volunteers. Thromb Haemost. 1994;71:305-313.
18. Brophy D, Wazny L, Gehr T, Comstock T, Venitz J. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease. Pharmacotherapy. 2001;21:169-174.
19. Casele H, Laifer S, Woelkers D, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1998;181:1113-1117.
20. Noble S, Peters D, Goa K. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs. 1995;49:388-410.
21. Levine MN, Planes A, Hirsch J, et al. The relationship between antifactor Xa level and clinical outcome in patients receiving enoxaprine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62:940-944.
22. Argenti D, Hoppensteadt D, Heald D, Jensen B, Fareed J. Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. Am J Ther. 2003;10:241-246.
23. White B, Perry D. Acquired anithrombin deficiency in sepsis. Br J Haematol. 2001;112:26-31.
24. Hoffmann J, Muhlbayer D, Jochum M, Inthorn D. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med. 2004;32:1851-1859.
25. Romisch J, Donges R, Stauss H, et al. Quantification of antithrombin isoform proportions in plasma samples of healthy subjects, sepsis patients, and in antithrombin concentrates. Pathophysiol Haemo Thromb. 2002;32:143-150.
26. Mammen E. Clinical relevance of antithrombin deficiencies. Semin Hematol. 1995;32(Suppl 2):2-6.
27. Leong C, Ong B. A case report of heparin resistance due to acquired antithrombin III deficiency. Ann Acad Med Singapore. 1998;27:877-879.
28. Ranucci M, Isgro G, Cazzaniga A, et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion. 1999;14:437-442.
29. Heller E, Paul L. Anticoagulation management in a patient with acquired antithrombin III deficiency. J Am Soc Extra-Corpor Tech. 2001;33:245-248.
30. Hermida J, Montes R, Munoz M, et al. Effects of low molecular weight heparin, along or combined with antithrombin III, on mortality, fibrin deposits and hemostatic parameters in endotoxin-induced disseminated intravascular coagulation in rabbits. Am J Hematol. 1999;60:6-11.
31. Ariza-Andraca C, Altamirano-Bustamante E, Frati-Munari A, Altamirano-Bustamante P, Graef-Sanchez A. Delayed insulin absorption due to subcutaneous edema. Arch Invest Med. 1991;22:229-233.
32. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833-1840.
33. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. Br Med J. 1991;303:543-548.